株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

眼底疾患:新薬とデリバリー技術

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

発行 ROOTS ANALYSIS 商品コード 597640
出版日 ページ情報 英文 292 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
眼底疾患:新薬とデリバリー技術 Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030
出版日: 2018年01月04日 ページ情報: 英文 292 Pages
概要

当レポートでは、眼底疾患の治療について調査分析し、新薬、薬剤デバイスの組み合わせ、技術に焦点を当てて、現在の市場情勢、地域情勢、パイプライン候補、ライフサイクル管理戦略、臨床段階の薬剤候補のプロファイル、現在利用可能な技術とデリバリーシステム、上市済み承認薬剤など、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 競合情勢

  • 概要
  • 臨床パイプライン
  • 前臨床/創薬パイプライン
  • 主要企業
  • 最も有望なハブ
  • 地域情勢
  • グリッド分析

第5章 製品ライフサイクル管理戦略

  • イントロダクション
  • Macugen
  • Lucentis
  • Eylea
  • Jetrea
  • Conbercept

第6章 薬剤プロファイル

  • 概要
  • LUXTURNA (Spark Therapeutics)
  • Sirolimus (Santen Pharmaceutical)
  • Abicipar Pegol (Molecular Partners/Allergan)
  • Brolucizumab (Alcon、Novartisの一部)
  • GS010 (GenSight Biologics)
  • Lampalizumab (Roche)
  • Optina (Ampio Pharmaceuticals)
  • Squalamine (OHR Pharmaceutical)
  • Zuretinol (Novelion Therapeutics)
  • Zimura (Ophthotech)

第7章 市場規模・機会分析

  • 概要
  • 調査手法と前提条件
  • 総合市場
  • 適応別
  • 薬剤分類別
  • 作用機序別
  • 投与経路別

第8章 技術プラットフォーム、デリバリーシステム、薬剤デバイスの組み合わせ

  • 概要
  • 製剤技術
  • ドラッグデリバリー技術/システム
  • 薬剤デバイスの組み合わせ/インプラント

第9章 義眼

  • 概要
  • 義眼・人工眼

第10章 パートナーシップとコラボレーション

  • 概要
  • パートナーシップモデル
  • パートナーシップのリスト
  • パートナーシップ分析

第11章 販促分析

  • 概要
  • 販促キャンペーンで使用するチャネル
  • サマリー:製品ウェブサイト分析
  • Macugen
  • Lucentis
  • Eylea
  • Jetrea

第12章 SWOT分析

第13章 結論

第14章 インタビュー

第15章〜第17章 付録

目次
Product Code: RA10097

According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Further, a recent study published in September 2017 estimates that the number of blind people is likely to increase to 38.5 million, by 2020, and to 115 million, by 2050. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be one of the main causes of vision loss globally, and an estimated 90% cases of visual impairment are reported to be caused due to such conditions. It is worth highlighting that a significant portion of these chronic ophthalmological disorders are clinical conditions related to the back of the eye.

The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that have an adverse impact on their therapeutic potential and adoption. Further, there are no treatment approaches available for a number of ophthalmological indications, such as dry age related macular degeneration (dry AMD), retinitis pigmentosa (RP) and leber congenital amaurosis. In order to overcome these challenges, various stakeholders are engaged in the development of novel therapeutic approaches. With the entry of several start-ups that are driving the innovation in this domain, the pipeline has several novel product candidates in various stages of development. Companies are steadily collaborating to develop and commercialize their products globally, in-license intellectual property to design new treatment modalities and advance research initiatives in this domain.

Synopsis:

The ‘Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030' report features an extensive study of the market for novel drugs, drug-device combinations and technologies for the treatment of back of the eye disorders. The focus of this study is on the applications and the likely evolution of novel treatment options (excluding steroids and corticosteroids) in the mid to long term. The evolving market has its hopes pinned on the efforts of multiple start-ups, small and large-sized companies. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of novel drugs, providing information on various drug / therapy developers, phase of development (clinical, preclinical or discovery stage) of product candidates, information on drug class, molecular target, type of therapy, mechanism of action, route of administration, and key therapeutic indication(s). In addition, we have provided a list of drug device combinations that target the back of the eye.
  • A world map representation, depicting the most active geographies in terms of the presence of companies developing drugs to treat back of the eye disorders.
  • A bull's eye analysis highlighting distribution of pipeline candidates in terms of phase of development, type of target and drug class. A grid analysis based on type of drug class developed / being developed across different indications and stages of development.
  • An elaborate discussion on lifecycle management strategies, depicting how companies are using various methods to expand patent exclusivity in order to exploit the revenue generation potential of their proprietary products.
  • Comprehensive profiles of clinical stage (phase II/III and above) drug candidates specifically targeting back of the eye disorders, highlighting their current status of development, mechanism of action, technology, patent portfolio, clinical trial information and recent developments.
  • A review of currently available technologies and delivery systems that are being used to administer therapeutics to the back of the eye, featuring brief profiles of the various technical advances, key benefits offered and information on the product candidates pipeline that are based on these technologies.
  • A discussion on various visual prosthesis that are available, highlighting their mechanism of action. In addition, we have provided a comparative 2X2 analysis of the different types visual prosthesis based on supplier power and product competitiveness.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and services agreements, and other relevant agreements.
  • A discussion on the key promotional strategies that have been adopted for marketing approved drugs, namely (based on the approval year) Macugen®, Lucentis®, Eylea® and Jetrea®, that are presently prescribed to treat back of the eye disorders.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. To account for the uncertainties associated with the development of novel drugs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. These include Elise Brownell (Senior Vice President of Operations and Project Management, Amarantus Bioscience), Quinton Oswald (President and CEO, Neurotech Pharmaceuticals) and Samantha Cobb (CEO, AdAlta). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Over 170 product candidates are currently under various stages of development for a diverse range of back of the eye disorders. 8 drugs are commercially available; of these, Lucentis® and Eylea® have already achieved blockbuster status. Nearly 40% of the pipeline molecules are under clinical development; specifically, 1 product candidates are in the pre-registration stage, 8 molecules are being investigated in phase III and phase II/III, 24 molecules in phase II, 27 molecules in phase I/II and 11 molecules in phase I clinical trials. Majority (56%) of the product candidates are still in the preclinical and discovery stages.
  • 2. Gene therapy has emerged as one of the key drug classes being investigated across various phases of development. One such therapy candidate, LUXTURNA™, which is being developed for the treatment of inherited RPE65 dystrophies, received approval from the USFDA for the treatment of patients with confirmed biallelic RPE65 mutation IRD in late 2017. Other important drug classes in this domain include small molecules (20%), antibody based therapeutics (12%), cell therapies (8%) and peptides / proteins (8%).
  • 3. 41% of the products in the pipeline are designed to treat age-related macular degeneration. Nearly 20% of the molecules are being developed for the treatment of diabetes associated eye disorders, such as diabetic macular edema and diabetic retinopathy. In addition, close to 14% of the molecules are under development for the treatment of retinitis pigmentosa, followed by Leber Hereditary Optic Neuropathy (5%) and Stargardt disease (3%). The remaining 17% of the pipeline molecules are being developed for treating posterior uveitis, Usher syndrome and other retinal dystrophies.
  • 4. Majority of product candidates (29%) in the clinical pipeline target various components of the anti-angiogenesis pathway. Most of the approved drugs (57%) also follow this particular mechanism of action. A significant number of molecules (18%) are being developed against various isoforms of VEGF; these molecules are designed to either target VEGF alone or in combination with other molecular targets.
  • 5. The market landscape is characterized by the presence of large-sized (20), mid-sized (21) and small-sized companies (69). Some of the prominent large-sized companies engaged in this domain include (in alphabetical order) AbbVie, Chengdu Kang Hong Pharmaceuticals, Genentech, Novartis, Pfizer, Regeneron Pharmaceuticals and Valeant Pharmaceuticals. Similarly, mid-sized companies that are actively contributing to the development of back of the eye disorders include (in alphabetical order) Acucela, Mitotech, Molecular Partners, Novelion Therapeutics, Quark Pharmaceuticals, Stealth Biotherapeutics and ThromboGenics. In addition, small companies, such as (in alphabetical order) Amyndas Pharmaceuticals, ElsaLys Biotech, Envisia Therapeutics, Exonate, GenSight Biologics, Ichor Therapeutics, InFlectis BioScience, Nightstar Therapeutics, Ocugen, Recursion Pharmaceuticals, SanBio and Vision Medicines are also actively involved in this domain.
  • 6. To overcome the challenges related to the effective delivery of drugs to the back of the eye, several innovative technologies are also being developed. Notable examples of advanced drug delivery technologies include (in alphabetical order) BioSeizer (Taiwan Liposome Company), Durasert™ (pSivida), Encapsulated Cell Therapy (Neurotech), EyeCET Platform Technology (Eyevensys) , EyeGate II® Delivery System (EyeGate Pharma), Ocular Drug Delivery System (GrayBug Vision), Oculis Platform Technology (Oculis), Replenish Posterior MicroPump™ (Replenish), SCS™ Microinjector (Clearside Biomedical), and Verisome Technology (Icon Bioscience).
  • 7. Given the increase in technological advancements, rise in the aging population across the globe and the unmet across multiple ophthalmological disorders, we anticipate the opportunity to steadily grow in the foreseen future. In fact, specific products, being developed for indications with very large target patient populations, are anticipated to achieve blockbuster status (sales over USD 1 billion) and become prime contributors to future revenues.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 13 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the back of the eye disorders market in the short-mid and long term.

Chapter 3 features a discussion on the general concepts related to the structure of the human eye, primarily focusing on the various disorders associated with the back of the eye. It provides information on the static, dynamic and metabolic barriers that have a significant impact on drug delivery to the back of the eye. The chapter also features a discussion on the different routes used to administer drugs into the eye. In addition, it covers details on the available treatment options (drug classes that have been approved or are currently under development) and drug delivery approaches for back of the eye disorders.

Chapter 4 includes information on over 175 therapeutics that are currently approved or are in different stages of development. It features a comprehensive analysis of the pipeline molecules, highlighting the drug developer, target indication, phase of development, drug class, type of therapy, mechanism of action and route of administration. In addition, it features a schematic representation on a world map, highlighting the key regional hubs developing therapeutics for the treatment of back of the eye disorders. Further, we have provided a logo landscape of product developers in North America, Europe and the Asia Pacific region on the basis of employee base. The chapter also features a comprehensive grid analysis of the various therapeutic product candidates, highlighting their respective target indications, drug class and phases of development.

Chapter 5 includes a detailed discussion on product life cycle management strategies that are being considered by developers of approved drugs. It focuses on the development and commercialization related strategies, which are being used extensively by drug developers to treat back of the eye disorders.

Chapter 6 contains detailed profiles of drugs that are in advanced stages of clinical development (phase II/III and above). Each profile provides information on the current status of development, mechanism of action, technology, patent portfolio, clinical trial information and recent developments.

Chapter 7 presents a comprehensive market forecast, highlighting the future potential of the market till 2030. Based on various parameters, such as target patient population, likely pricing and adoption (driven by clinical efficacy and safety data), we have estimated the evolution of the market over the coming 10-15 years. The chapter provides detailed segmentation of overall opportunity based on drug classes (antibody based therapeutics, fusion proteins, peptides, small molecules, oligonucleotides and others), indications (wet AMD, dry AMD, DME, DR, LHON, Stargardt disease and others), mechanism of action (anti-angiogenesis, anti-inflammatory, complement pathway inhibition, functional protein production, visual cycle modulation and others) and route of administration (intravitreal, topical, oral, subcutaneous and others).

Chapter 8 provides details on the technology platforms and drug delivery systems that have been developed to address the challenges posed by the current treatment approaches in this space. It includes brief profiles of those drug delivery technologies / platforms that are being developed for multiple drug candidates in the clinical stage. Each profile provides information on the developer, key advantages, release profile, type of molecule and technology pipeline. In addition, the chapter highlights the various ocular implants / drug device combinations that are either approved or being developed to target back of the eye disorders.

Chapter 9 highlights the bionic vision technology / visual prostheses, which are designed to restore vision in visually impaired patients. It includes information on the various bionic eye technologies that are either approved or currently in various stages of development for the treatment of back of the eye disorders, specifically RP and wet AMD. It also presents a comparative 2 X 2 matrix analysis of bionic vision technologies, based on parameters, such as phase of development, site of implantation, targeted indications and unique characteristics of these technologies.

Chapter 10 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial collaborations) and the most common forms of deals / agreements that have been established between 2013 and 2017 (including both the years).

Chapter 11 highlights the key promotional strategies that are being implemented by the developers of marketed products, such as Macugen®, Lucentis®, Eylea® and Jetrea®. For the purpose of this analysis, we studied the promotional activities undertaken by the developers of the aforementioned drugs. The promotional aspects covered in the chapter include details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 12 provides a detailed analysis, capturing the key parameters and trends that are likely to influence the future of the back of the eye disorders market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 13 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Elise Brownell (Senior Vice President of Operations and Project Management, Amarantus Bioscience), Quinton Oswald (President and CEO, Neurotech Pharmaceuticals) and Samantha Cobb (CEO, AdAlta).

Chapter 15 is an appendix, which provides information on drugs that have been discontinued over time.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Background and Context
  • 3.2. Structure of the Eye
  • 3.3. Components of Back of the Eye
    • 3.3.1. Retina
    • 3.3.2. Vitreous Humor
    • 3.3.3. Optic Nerve
  • 3.4. The Visual Cycle
  • 3.5. Barriers to the Back of the Eye
    • 3.5.1. Static Barriers
    • 3.5.2. Dynamic Barriers
    • 3.5.3. Metabolic Barriers
  • 3.6. Route of Administration of Drugs to Back of the Eye
  • 3.7. Disorders Associated with Back of the Eye
  • 3.8. Treatment Options for Back of the Eye Disorders
    • 3.8.1. Laser Treatment
    • 3.8.2. Vitrectomy / Vitreous Surgery
    • 3.8.3. Drugs
      • 3.8.3.1. Angiogenesis Inhibitors
      • 3.8.3.2. Complement Factor Inhibitors
      • 3.8.3.3. Visual Cycle Modulators
      • 3.8.3.4. Anti-Inflammatory Drugs
      • 3.8.3.5. Gene Therapies
      • 3.8.3.6. Stem Cell Therapies
  • 3.9. Drug Delivery Platforms for Back of the Eye Disorders
    • 3.9.1. Implantable Devices
    • 3.9.2. Intravitreal Injections
    • 3.9.3. Depot Injections
    • 3.9.4. Transscleral Iontophoresis
    • 3.9.5. Nanotechnology
    • 3.9.6. Encapsulated Cell Technology

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Back of the Eye Disorders: Clinical Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Drug Class
    • 4.2.3. Analysis by Mechanism of Action
    • 4.2.4. Analysis by Type of Molecular Target
    • 4.2.5. Analysis by Target Indication
    • 4.2.6. Analysis by Type of Therapy
    • 4.2.7. Analysis by Route of Administration
  • 4.3. Back of the Eye Disorders: Preclinical / Discovery Pipeline
    • 4.3.1. Analysis by Drug Class
    • 4.3.2. Analysis by Target Indication
  • 4.4. Back of the Eye Disorders Pipeline: Leading Players
  • 4.5. Back of the Eye Disorders Pipeline: Most Prominent Hubs
  • 4.6. Back of the Eye Disorders Pipeline: Regional Landscape
  • 4.7. Back of the Eye Disorders Pipeline: Grid Analysis

5. PRODUCT LIFE CYCLE MANAGEMENT STRATEGIES

  • 5.1. Introduction
  • 5.2. Macugen®
    • 5.2.1. Overview
    • 5.2.2. Mechanism of Action
    • 5.2.3. Life Cycle Management Strategy
      • 5.2.3.1. Geographic Expansion
      • 5.2.3.2. Development of New Formulation
    • 5.2.4. Collaborations
  • 5.3. Lucentis®
    • 5.3.1. Overview
    • 5.3.2. Mechanism of Action
    • 5.3.3. Life Cycle Management Strategy
      • 5.3.3.1. Indication and Geographic Expansion
      • 5.3.3.2. Strategic Pricing
      • 5.3.3.3. Development of New Formulation
      • 5.3.3.4. Development of Combination Therapies
    • 5.3.4. Collaborations
  • 5.4. Eylea®
    • 5.4.1. Overview
    • 5.4.2. Mechanism of Action
    • 5.4.3. Life Cycle Management Strategy
      • 5.4.3.1. Indication and Geographic Expansion
      • 5.4.3.2. Therapeutic Area Expansion
      • 5.4.3.3. Development of an Intravitreal Depot
      • 5.4.3.4. Strategic Pricing and Reimbursement
      • 5.4.3.5. Development of Combination Therapies
    • 5.4.4. Collaborations
  • 5.5. Jetrea®
    • 5.5.1. Overview
    • 5.5.2. Mechanism of Action
    • 5.5.3. Life Cycle Management Strategy
      • 5.5.3.1. Indication and Geographic Expansion
      • 5.5.3.2. Development of New Formulation
      • 5.5.3.3. Reimbursement Strategies
    • 5.5.4. Collaborations
  • 5.6. Conbercept
    • 5.6.1. Overview
    • 5.6.2. Mechanism of Action
    • 5.6.3. Life Cycle Management Strategy
      • 5.6.3.1. Indication Expansion

6. DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. LUXTURNA™ (Spark Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.3. Sirolimus (Santen Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.4. Abicipar Pegol (Molecular Partners / Allergan): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.5. Brolucizumab (Alcon, a Division of Novartis): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.6. GS010 (GenSight Biologics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.7. Lampalizumab (Roche): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.8. Optina (Ampio Pharmaceuticals): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.9. Squalamine (OHR Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.10. Zuretinol (Novelion Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
  • 6.11. Zimura (Ophthotech): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results

7. MARKET SIZE AND OPPORTUNITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Forecast Methodology and Key Assumptions
  • 7.3. Overall Back of the Eye Disorders Market, 2017-2030
  • 7.4. Back of the Eye Disorders Market: Distribution by Indications
    • 7.4.1. Back of the Eye Disorders Market for Wet Age-related Macular Degeneration (AMD)
    • 7.4.2. Back of the Eye Disorders Market for Dry AMD
    • 7.4.3. Back of the Eye Disorders Market for Diabetic Macular Edema (DME)
    • 7.4.4. Back of the Eye Disorders Market for Diabetic Retinopathy (DR)
    • 7.4.5. Back of the Eye Disorders Market for Stargardt Disease
    • 7.4.6. Back of the Eye Disorders Market for Leber Hereditary Optic Neuropathy (LHON)
    • 7.4.7. Back of the Eye Disorders Market for Other Indications
  • 7.5. Back of the Eye Disorders Market: Distribution by Drug Class
  • 7.6. Back of the Eye Disorders Market: Distribution by Mechanism of Action
  • 7.7. Back of the Eye Disorders Market: Distribution by Route of Administration

8. TECHNOLOGY PLATFORMS, DELIVERY SYSTEMS AND DRUG DEVICE COMBINATIONS

  • 8.1. Chapter Overview
  • 8.2. Drug Formulation Technologies
  • 8.3. Drug Delivery Technologies / Systems
    • 8.3.1. Profiles of Key Drug Delivery Technologies / Systems
      • 8.3.1.1. BioSeizer (Taiwan Liposome Company): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.2. Durasert™ (pSivida): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.3. Encapsulated Cell Therapy (Neurotech Pharmaceuticals): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.4. EyeCET Platform Technology (Eyevensys): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.5. EyeGate II® Delivery System (EyeGate Pharma): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.6. Ocular Drug Delivery Technology (Graybug Vision): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.7. Oculis Platform Technology (Oculis): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.8. Replenish Posterior MicroPump™ (Replenish): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.9. SCS™ Microinjector (Clearside Biomedical): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
      • 8.3.1.10. Verisome (Icon Bioscience): Type of Technology, Key Features, Sustained Release (Duration), Type of Molecules and Technology Pipeline
  • 8.4. Drug Device Combinations / Implants

9. VISUAL PROSTHESIS

  • 9.1. Chapter Overview
  • 9.2. Visual Prosthesis / Bionic Eye
    • 9.2.1. Architecture
    • 9.2.2. Role in the Treatment of Retinal Disorders
    • 9.2.3. Market Landscape
      • 9.2.3.1. Product Competitiveness Analysis

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Back of the Eye Disorders: List of Partnerships
  • 10.4. Back of the Eye Disorders: Partnerships Analysis
    • 10.4.1. Analysis by Year of Partnership
    • 10.4.2. Analysis by Type of Partnership Model
    • 10.4.3. Most Active Players by Number of Partnerships

11. PROMOTIONAL ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Channels Used for Promotional Campaigns
  • 11.3. Summary: Product Website Analysis
    • 11.3.1. Summary: Patient Support Services and Informative Downloads
  • 11.4. Promotional Analysis: Macugen®
    • 11.4.1. Drug Overview
    • 11.4.2. Product Website Analysis
      • 11.4.2.1. Patient Assistance Program
      • 11.4.2.2. Distributor Information and Informative Downloads
  • 11.5. Promotional Analysis: Lucentis®
    • 11.5.1. Drug Overview
    • 11.5.2. Product Website Analysis
      • 11.5.2.1. Messages for Healthcare Professionals
      • 11.5.2.2. Patient Support Services and Informative Downloads
      • 11.5.2.3. Messages for Patients and Caregivers
      • 11.5.2.4. Other Promotional Activities
  • 11.6. Promotional Analysis: Eylea®
    • 11.6.1. Drug Overview
    • 11.6.2. Product Website Analysis
      • 11.6.2.1. Messages for Healthcare Professionals
      • 11.6.2.2. Patient Support Services and Informative Downloads
      • 11.6.2.3. Messages for Patients and Caregivers
  • 11.7. Promotional Analysis: Jetrea®
    • 11.7.1. Drug Overview
    • 11.7.2. Product Website Analysis
      • 11.7.2.1. Messages for Healthcare Professionals
      • 11.7.2.2. Patient Support Services and Informative Downloads
      • 11.7.2.3. Messages for Patients and Caregivers
      • 11.7.2.4. Promoting New Formulation of Jetrea®
      • 11.7.2.5. Platform to Report Adverse Events Associated with the Drug

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. CONCLUSION

  • 13.1. The Back of the Eye Disorders Market is Characterized by a Robust Pipeline of Candidates Belonging to Different Drug Classes
  • 13.2. Although Product Candidates are Being Developed to Treat a Number of Clinical Conditions, the Primary Focus is on Macular Degenerative Disorders
  • 13.3. Increasing Partnerships Activity to Support Drug Development is Indicative of Future Opportunity
  • 13.4. Currently, the Market is Led by Big Pharma Players; Many Start-ups, Though, are Making Significant Strides in this Domain
  • 13.5. Multiple Novel Delivery Approaches are Being Investigated to Assist in Improving Patient Compliance
  • 13.6. Given the Presence of Blockbuster Drugs, and Several Late Stage Product Candidates, the Market is Poised to Grow Steadily in the Foreseen Future

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Elise Brownell, Senior Vice President of Operations and Project Management, Amarantus Bioscience
  • 14.3. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
  • 14.4 Samantha Cobb, CEO, AdAlta

15. APPENDIX: LIST OF DISCONTINUED MOLECULES

16. APPENDIX: TABULATED DATA

17. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Structure of Eye
  • Figure 3.2: Structure of Retina
  • Figure 3.3: Back of the Eye: Barriers
  • Figure 3.4: Back of the Eye: Routes of Administration
  • Figure 3.5: Back of the Eye Disorders: Treatment Options
  • Figure 3.6: Back of the Eye Disorders: Marketed Angiogenesis Inhibitors
  • Figure 3.7: Back of the Eye Disorders: Delivery Approaches
  • Figure 3.8: Back of the Eye Disorders: Marketed Implants
  • Figure 4.1: Back of the Eye Disorders, Clinical Pipeline: Distribution by Phase of Development
  • Figure 4.2: Back of the Eye Disorders, Clinical Pipeline: Distribution by Drug Class
  • Figure 4.3: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Pathway
  • Figure 4.4: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Molecular Target (Cumulative)
  • Figure 4.5: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Molecular Target (Individual)
  • Figure 4.6: Back of the Eye Disorders, Clinical Pipeline: Distribution by Target Indication
  • Figure 4.7: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Therapy
  • Figure 4.8: Back of the Eye Disorders, Clinical Pipeline: Distribution by Route of Administration
  • Figure 4.9: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Phase of Development
  • Figure 4.10: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Drug Class
  • Figure 4.11: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Target Indication
  • Figure 4.12: Back of the Eye Disorders Pipeline: Leading Players
  • Figure 4.13: Back of the Eye Disorders Pipeline: Most Prominent Hubs
  • Figure 4.14: Back of the Eye Disorders Pipeline: Developer Landscape, North America
  • Figure 4.15: Back of the Eye Disorders Pipeline: Developers Landscape, Europe
  • Figure 4.16: Back of the Eye Disorders Pipeline: Developers Landscape, Asia Pacific
  • Figure 4.17: Back of the Eye Disorders Pipeline: Grid Analysis
  • Figure 5.1: Life Cycle Management Strategies
  • Figure 5.2: Macugen®: Mechanism of Action
  • Figure 5.3: Macugen®: Life Cycle Management
  • Figure 5.4: Lucentis®: Mechanism of Action
  • Figure 5.5: Lucentis®: Life Cycle Management
  • Figure 5.6: Lucentis®: Timeline of Approved Indications (US)
  • Figure 5.7: Lucentis®: Timeline of Approved Indications (Europe)
  • Figure 5.8: Lucentis®: Price (Annual Treatment Cost) Evolution Strategy (EU)
  • Figure 5.9: Eylea®: Mechanism of Action
  • Figure 5.10: Eylea®: Life Cycle Management
  • Figure 5.11: Eylea®: Timeline of Approved Indications
  • Figure 5.12: Jetrea®: Life Cycle Management
  • Figure 5.13: Jetrea®: Geographic Expansion
  • Figure 5.14: Conbercept: Mechanism of Action
  • Figure 5.15: Conbercept: Life Cycle Management
  • Figure 7.1: Overall Back of the Eye Disorders Market, 2017-2030 (USD Billion)
  • Figure 7.2: Overall Back of the Eye Disorders Market: Market Attractiveness Analysis by Indication, 2023-2030
  • Figure 7.3: Back of the Eye Disorders Market: Wet AMD, 2017-2030, Base Scenario (USD Billion)
  • Figure 7.4: Back of the Eye Disorders Market: Dry AMD, 2021-2030, Base Scenario (USD Billion)
  • Figure 7.5: Back of the Eye Disorders Market: DME, 2017-2030, Base Scenario (USD Billion)
  • Figure 7.6: Back of the Eye Disorders Market: DR, 2017-2030, Base Scenario (USD Billion)
  • Figure 7.7: Back of the Eye Disorders Market: Stargardt Disease, 2023-2030, Base Scenario (USD Billion)
  • Figure 7.8: Back of the Eye Disorders Market: LHON, 2017-2030, Base Scenario (USD Billion)
  • Figure 7.9: Back of the Eye Disorders Market: Other Indications, 2017-2030, Base Scenario (USD Billion)
  • Figure 7.10: Back of the Eye Disorders Market: Distribution by Drug Classes, 2017 and 2030
  • Figure 7.11: Back of the Eye Disorders Market: Distribution by Mechanism of Action, 2017 and 2030
  • Figure 7.12: Back of the Eye Disorders Market: Distribution by Route of Administration, 2017 and 2030
  • Figure 8.1: Back of the Eye: Drug Delivery Technologies
  • Figure 9.1: Visual Prosthesis / Bionic Eye: External and Implantable Modules
  • Figure 9.2: Visual Prosthesis / Bionic Eye: Steps of Operation
  • Figure 9.3: Visual Prosthesis / Bionic Eye: Product Competitiveness Analysis
  • Figure 10.1: Back of the Eye Disorders Partnerships: Cumulative Trend (2013-2017)
  • Figure 10.2: Back of the Eye Disorders Partnerships: Distribution by Type of Partnership Model
  • Figure 10.3: Back of the Eye Disorders Partnerships: Most Active Players, 2013-2017
  • Figure 11.1: Promotional / Marketing Strategy: Product Website Analysis
  • Figure 11.2: Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 11.3: Product Website Analysis: Macugen®, Focus on Access Program
  • Figure 11.4: Product Website Analysis: Macugen®, Distributor Information
  • Figure 11.5: Product Website Analysis: Lucentis®, Messages for Healthcare Professionals
  • Figure 11.6: Product Website Analysis: Lucentis®, Patient Support Program
  • Figure 11.7: Product Website Analysis: Lucentis®, Direct Program
  • Figure 11.8: Product Website Analysis: Lucentis®, Co-pay Card Program
  • Figure 11.9: Product Website Analysis: Lucentis®, Access Solutions
  • Figure 11.10: Product Website Analysis: Lucentis®, Genentech Access to Care Foundation
  • Figure 11.11: Product Website Analysis: Lucentis®, Messages for Patients
  • Figure 11.12: Product Website Analysis: Eylea®, inSight Platform
  • Figure 11.13: Product Website Analysis: Eylea®, Messages for Healthcare Professionals
  • Figure 11.14: Product Website Analysis: Eylea®, Patient Assistance Program
  • Figure 11.15: Product Website Analysis: Eylea®, Co-pay Card Program
  • Figure 11.16: Product Website Analysis: Eylea®, Co-pay Assistance Referral Program
  • Figure 11.17: Product Website Analysis: Eylea®, Messages for Patients and Caregivers
  • Figure 11.18: Product Website Analysis: Jetrea®, Messages for Healthcare Professionals
  • Figure 11.19: Product Website Analysis: Jetrea®, Clinical Trial and Dosing Information
  • Figure 11.20: Product Website Analysis: Jetrea®, JETREA CARE® Program
  • Figure 11.21: Product Website Analysis: Jetrea®, Co-pay Payment Portal
  • Figure 11.22: Product Website Analysis: Jetrea®, Distributor Information
  • Figure 11.23: Product Website Analysis: Jetrea®, Messages for Patients and Caregivers
  • Figure 11.24: Product Website Analysis: Jetrea®, Information on New Formulation
  • Figure 11.25: Product Website Analysis: Jetrea®, Information on Platform for Reporting Adverse Events
  • Figure 12.1: Back of the Eye Disorders SWOT Analysis: Overview
  • Figure 12.2: Back of the Eye Disorders SWOT Analysis: Strengths
  • Figure 12.3: Back of the Eye Disorders SWOT Analysis: Weaknesses
  • Figure 12.4: Back of the Eye Disorders SWOT Analysis: Opportunities
  • Figure 12.5: Back of the Eye Disorders SWOT Analysis: Threats
  • Figure 13.1: Back of the Eye Disorders: Clinical Stage Molecules by Key Drug Targets and Drug Classes
  • Figure 13.2: Back of the Eye Disorders: Key Disease Indications
  • Figure 13.3: Back of the Eye Disorders Market: Conservative, Base and Optimistic Forecast Scenarios, 2024 and 2030 (USD Billion)

List of Tables:

  • Table 3.1: Tissue Layers of the Eye
  • Table 3.2: Overview of Major Back of the Eye Disorders
  • Table 3.3: Back of the Eye Disorders: Marketed Implants
  • Table 4.1: Back of the Eye Disorders: Clinical Pipeline
  • Table 4.2: Back of the Eye Disorders: Preclinical Pipeline
  • Table 5.1: Differences between Eylea® and Zaltrap
  • Table 6.1: Back of the Eye Disorders: Late Stage Product Candidates
  • Table 8.1: Back of the Eye Disorders: Drug Formulation Technologies
  • Table 8.2: Back of the Eye Disorders: Drug Delivery Technologies / Systems
  • Table 8.3: List of Drug Device Combinations / Implants
  • Table 9.1: List of Visual Prosthesis / Bionic Eye
  • Table 10.1: Back of the Eye Disorders: Partnerships
  • Table 11.1: Macugen®: Drug Overview
  • Table 11.2: Lucentis®: Drug Overview
  • Table 11.3: Eylea®: Drug Overview
  • Table 11.4: Jetrea®: Drug Overview
  • Table 16.1: Back of the Eye Disorders, Clinical Pipeline: Distribution by Phase of Development
  • Table 16.2: Back of the Eye Disorders, Clinical Pipeline: Distribution by Drug Class
  • Table 16.3: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Pathway
  • Table 16.4: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Molecular Target (Cumulative)
  • Table 16.5: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Molecular Target (Individual)
  • Table 16.6: Back of the Eye Disorders, Clinical Pipeline: Distribution by Target Indication
  • Table 16.7: Back of the Eye Disorders, Clinical Pipeline: Distribution by Type of Therapy
  • Table 16.8: Back of the Eye Disorders, Clinical Pipeline: Distribution by Route of Administration
  • Table 16.9: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Phase of Development
  • Table 16.10: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Drug Class
  • Table 16.11: Back of the Eye Disorders, Preclinical Pipeline: Distribution by Target Indication
  • Table 16.12: Back of the Eye Disorders Pipeline: Leading Players
  • Table 16.13: Overall Back of the Eye Disorders Market, 2017-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.14: Overall Back of the Eye Disorders Market: Market Attractiveness Analysis by Indication, 2023-2030
  • Table 16.15: Back of the Eye Disorders Market: Wet AMD, 2017 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.16: Back of the Eye Disorders Market: Dry AMD, 2021 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.17: Back of the Eye Disorders Market: DME, 2017 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.18: Back of the Eye Disorders Market: DR, 2017 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.19: Back of the Eye Disorders Market: Stargardt Disease, 2023 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.20: Back of the Eye Disorders Market: LHON, 2017 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.21: Back of the Eye Disorders Market: Other Indications, 2017 - 2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 16.22: Back of the Eye Disorders Market: Distribution by Drug Classes, 2017 and 2030
  • Table 16.23: Back of the Eye Disorders Market: Distribution by Mechanism of Action, 2017 and 2030
  • Table 16.24: Back of the Eye Disorders Market: Distribution by Route of Administration, 2017 and 2030
  • Table 16.25: Back of the Eye Disorders Partnerships: Cumulative Trend (2013-2017)
  • Table 16.26: Back of the Eye Disorders Partnerships: Distribution by Type of Partnership Model
  • Table 16.27: Back of the Eye Disorders Market: Conservative, Base and Optimistic Forecast Scenarios, 2024 and 2030 (USD Billion

Listed Companies:

The following companies and organizations have been mentioned in the report.

  • 1. 4D Molecular Therapeutics
  • 2. AbbVie
  • 3. Academy of Finland
  • 4. Accredo Health Group
  • 5. Achillion Pharmaceuticals
  • 6. Aciont
  • 7. ActiveSite Pharmaceuticals
  • 8. Acucela
  • 9. AdAlta
  • 10. Adverum Biotechnologies
  • 11. Aegerion Pharmaceuticals
  • 12. Aerie Pharmaceuticals
  • 13. Aerpio Therapeutics
  • 14. Affilogic
  • 15. AGTC
  • 16. Alcon (a Novartis division)
  • 17. Alfred Hospital
  • 18. Alimera Sciences
  • 19. Alkeus Pharmaceuticals
  • 20. Allegro Ophthalmics
  • 21. Allergan
  • 22. Allinky Biopharma
  • 23. ALTEOGEN
  • 24. Amarantus BioScience
  • 25. Amarna Therapeutics
  • 26. Ampio Pharmaceuticals
  • 27. Amyndas Pharmaceuticals
  • 28. Apellis Pharmaceuticals
  • 29. Apexian Pharmaceuticals
  • 30. Apexigen
  • 31. Apollo Endosurgery
  • 32. Appletree CI Group
  • 33. Araim Pharmaceuticals
  • 34. Ascendis Pharma
  • 35. AsclepiX Therapeutics
  • 36. Astellas Institute for Regenerative Medicine (AIRM)
  • 37. Astellas Pharma
  • 38. Athena Vision
  • 39. AyuVis Research
  • 40. Bascom Palmer Eye Institute
  • 41. Bausch + Lomb
  • 42. Bayer
  • 43. BCM Families Foundation
  • 44. Benitec Biopharma
  • 45. Besse Medical
  • 46. Bicycle Therapeutics
  • 47. BIOCND
  • 48. Biogen
  • 49. BioInvent
  • 50. Biokine Therapeutics
  • 51. BioLight Lifesciences
  • 52. Bionic Sight
  • 53. Bionic Vision Technologies (BVT)
  • 54. BIOPHYTIS
  • 55. BioTime
  • 56. Biovista
  • 57. Case Western Reserve University (CWRU)
  • 58. Catalent
  • 59. Catalyst Biosciences
  • 60. Université catholique de Louvain
  • 61. Cellular Dynamics International (CDI)
  • 62. Ceregene
  • 63. Charlesson
  • 64. Chengdu Kanghong Pharmaceuticals Group
  • 65. Children's Hospital of Philadelphia
  • 66. Cipla BioTec
  • 67. Clanotech
  • 68. Clearside Biomedical
  • 69. Clonz Biotech
  • 70. Coherus Biosciences
  • 71. Columbia University
  • 72. CoMentis
  • 73. Copernicus Therapeutics
  • 74. Critical Pharmaceuticals
  • 75. CuraScript SD
  • 76. CVS Caremark
  • 77. Daiichi Sankyo
  • 78. DelSiTech
  • 79. Dompé
  • 80. Editas Medicine
  • 81. Eleven Biotherapeutics
  • 82. ElsaLys Biotech
  • 83. Envisia Therapeutics
  • 84. Exonate
  • 85. EyeGate Pharma
  • 86. Eyemedics
  • 87. Eyetech Pharmaceuticals
  • 88. Eyevensys
  • 89. Ferrer
  • 90. Fondation Voir et Entendre
  • 91. Formycon
  • 92. ForSight VISION 4
  • 93. Foundation Fighting Blindness (FFB)
  • 94. FUJIFILM Holdings
  • 95. Galapagos
  • 96. Galaxy Ophthalmics
  • 97. Gemini Therapeutics
  • 98. Genable Technologies
  • 99. Gene Signal
  • 100. Gene Techno Science
  • 101. Genaera Corporation
  • 102. Genentech
  • 103. Genethon
  • 104. GenSight Biologics
  • 105. Gilead Sciences
  • 106. Graybug Vision
  • 107. Grey Innovation
  • 108. GlaxoSmithKline (GSK)
  • 109. Gunma University
  • 110. Hadassah Medical Center
  • 111. Hanmi Pharmaceutical
  • 112. Harvard Medical School (HMS)
  • 113. Healios
  • 114. Hemera Biosciences
  • 115. Henogen (a subsidiary of the Novasep group)
  • 116. HORAMA
  • 117. Huabo Biopharm
  • 118. i2KKKKK Pharmaceuticals
  • 119. Ichor Therapeutics
  • 120. Icon Bioscience
  • 121. Iconic Therapeutics
  • 122. Illinois Institute of Technology
  • 123. Inception Sciences
  • 124. InFlectis BioScience
  • 125. InnoCore Pharma
  • 126. Innovent Biologics
  • 127. Intas Pharmaceuticals
  • 128. Intrexon
  • 129. Ionis Pharmaceuticals
  • 130. I'rom Group
  • 131. Ixchel Pharma
  • 132. Janssen
  • 133. jCyte
  • 134. Jeil Pharmaceutical
  • 135. Jiangsu T-mab BioPharma
  • 136. Johns Hopkins University
  • 137. K.N. Toosi University of Technology
  • 138. Kala Pharmaceuticals
  • 139. Kalos Therapeutics
  • 140. KalVista Pharmaceuticals
  • 141. KMG Pharma
  • 142. Kodiak Sciences
  • 143. Kowa Company
  • 144. Laboratoire de Génétique Médicale de Strasbourg
  • 145. LeadArtis
  • 146. Lin Bio Science
  • 147. Lonza
  • 148. Loyola University Chicago
  • 149. Lpath
  • 150. Massachusetts General Hospital
  • 151. Massachusetts Institute of Technology (MIT)
  • 152. McKesson
  • 153. Medical College of Wisconsin (MCW)
  • 154. MeiraGTx
  • 155. Memorial Sloan Kettering Cancer Center
  • 156. Merck
  • 157. MimeTech
  • 158. Mimetogen Pharmaceuticals
  • 159. MiniFAB
  • 160. Mitotech
  • 161. Molecular Partners
  • 162. Monash University
  • 163. MorphoSys
  • 164. Mosaic Biosciences
  • 165. M's Science Corporation
  • 166. Mystic Pharmaceuticals
  • 167. Nano Retina
  • 168. Nanovision
  • 169. National Institutes of Health (NIH)
  • 170. Nektar Therapeutics
  • 171. Neovacs
  • 172. Neurotech Pharmaceuticals
  • 173. NeXstar Pharmaceuticals
  • 174. Novartis
  • 175. Novelion Therapeutics
  • 176. Ocata Therapeutics
  • 177. OccuRx
  • 178. Ocugen
  • 179. Ocular Therapeutix
  • 180. Oculis
  • 181. OcuNexus Therapeutics
  • 182. Odylia Therapeutics
  • 183. Ohr Pharmaceutical
  • 184. OliX Pharmaceuticals
  • 185. Omeros
  • 186. Opthea
  • 187. Ophthotech
  • 188. Opsis Therapeutics
  • 189. Optobionics
  • 190. Casey Eye Institute, Oregon Health & Science University (OHSU)
  • 191. Osaka University
  • 192. Oxford BioMedica
  • 193. Oxular
  • 194. Paloma Pharmaceuticals
  • 195. Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse
  • 196. PanOptica
  • 197. Patheon
  • 198. Pfenex
  • 199. Pfizer
  • 200. Pieris Pharmaceuticals
  • 201. Pixium Vision
  • 202. Polus
  • 203. PolyActiva
  • 204. Potentia Pharmaceuticals
  • 205. Preceyes
  • 206. ProLynx
  • 207. Promedior
  • 208. ProQR
  • 209. Proretina Therapeutics
  • 210. Proteostasis Therapeutics
  • 211. pSivida
  • 212. Qilu Pharmaceuticals
  • 213. Quark Pharmaceuticals
  • 214. Ra Pharma
  • 215. Recursion Pharmaceuticals
  • 216. Regeneron Pharmaceuticals
  • 217. REGENXBIO
  • 218. Reliance RX
  • 219. ReNeuron
  • 220. Replenish
  • 221. Retina Foundation of the Southwest
  • 222. Retina Implant
  • 223. Retinagenix
  • 224. RetroSense Therapeutics
  • 225. Ribomic
  • 226. Roche
  • 227. Royal DSM
  • 228. RWTH Aachen University
  • 229. RXi Pharmaceuticals
  • 230. Saksin Lifesciences
  • 231. Samsung Bioepis
  • 232. SanBio
  • 233. Sanofi
  • 234. Santen Pharmaceuticals
  • 235. Santhera Pharmaceuticals
  • 236. Santo Holding
  • 237. SciFluor Life Sciences
  • 238. Second Sight
  • 239. Selexis
  • 240. SENJU Pharmaceutical
  • 241. SENS Research Foundation
  • 242. SGS Life Science
  • 243. Shanghai Jiao-Tong University
  • 244. Sonikure Technology
  • 245. Spark Therapeutics
  • 246. Stanford University
  • 247. Stealth BioTherapeutics
  • 248. Sumitomo Dainippon Pharma
  • 249. Sun Pharmaceutical
  • 250. Syracuse University
  • 251. Taiwan Liposome Company
  • 252. Tanox
  • 253. Massachusetts Eye and Ear Infirmary
  • 254. The University of Manchester
  • 255. University of Massachusetts Medical School
  • 256. University of Pennsylvania
  • 257. TheraKine
  • 258. ThromboGenics
  • 259. TRACON Pharmaceuticals
  • 260. University of Tübingen
  • 261. Tyrogenex
  • 262. UCL Business
  • 263. Universal Cells
  • 264. University License Equity Holding (ULEHI), University of Colorado
  • 265. University of California
  • 266. University of Melbourne
  • 267. University of Pittsburgh Medical Center (UPMC)
  • 268. University of Utah
  • 269. University of Virginia School of Medicine
  • 270. VAXIER THERAPEUTICS
  • 271. Versant Ventures
  • 272. Verseon
  • 273. VESSL Therapeutics
  • 274. Vision Medicines
  • 275. Vision Technologies
  • 276. Walgreens Specialty Pharmacy
  • 277. Wellstat Ophthalmics Corporation
  • 278. WuXi AppTec
  • 279. Xbrane Biopharma
  • 280. XL Vision Sciences
Back to Top